Medical Device BPO Services Across the Full Device Lifecycle

Ameridial provides six medical device BPO service areas: Medical Device Customer Service and Remote Monitoring Support; Patient Onboarding and Device Education; Tier 1 Technical Support (non-clinical); Medical Device Order Tracking and Fulfilment Support; Adverse Event Reporting and Complaint Intake (aligned to FDA 21 CFR Part 803); and Medical Device Recall Notification Services. DME Support Services is also available for durable medical equipment suppliers. All services are non-clinical and delivered within HIPAA-compliant, SOC 2 Type II-audited environments.

Ameridial’s adverse event intake workflows are designed to operate in alignment with FDA 21 CFR Part 803 (Medical Device Reporting) requirements. Trained agents follow manufacturer-approved intake scripts to capture complete complaint data, classify reportability, and route information accurately to the manufacturer’s internal quality and regulatory teams. Ameridial does not make MDR reportability determinations — that responsibility remains with the manufacturer’s regulatory team — but our structured intake and documentation processes are designed to support manufacturers’ MDR-obligated reporting timelines and MAUDE submission workflows.

No. Ameridial provides non-clinical customer support, technical assistance, onboarding coordination, and regulatory intake services only. All clinical assessment, diagnosis, or medical decision-making remains exclusively with licensed healthcare professionals. Agent training, workflow design, and AI-assisted quality monitoring all enforce this non-clinical boundary during every interaction.

Ameridial supports medical device manufacturers (including Class II and Class III device companies), DME suppliers (CPAP, mobility devices, diabetes devices, home health equipment), digital health and RPM platform providers, connected health companies, and specialty device manufacturers. Within MedTech, Ameridial has particular experience supporting diabetes device companies, sleep apnea and CPAP suppliers, diagnostic and monitoring device companies, and mobility device providers.

Most medical device BPO programs launch within 4–8 weeks, depending on device complexity, manufacturer-specific script and protocol development, system integration requirements, and program scope. FDA-aligned adverse event intake programs may require additional time for workflow validation and agent compliance training. Recall notification programs can typically be activated on accelerated timelines given the urgency of recall events — Ameridial’s implementation team is experienced in rapid deployment for time-sensitive device safety communications.

Still have questions?
Schedule a consultation with our team.